Abstracts

SINGLE-CELL ATLAS AND CLONAL EXPANSION DYNAMICS OF CD4+ T CELLS DURING HIV INFECTION

Despite effective antiretroviral therapy (ART), HIV-1 persists in CD4+ T cells as a major barrier to cure. More than 50% of the HIV-1 latent reservoir is maintained by clonal expansion. HIV-1-infected cells undergo clonal expansion through antigen-driven proliferation, homeostatic proliferation and integration site-driven proliferation. Targeting clonally expanding HIV-1-infected cells without damaging uninfected cells is required…

SURFACE ENGINEERING OF EXTRACELLULAR VESICLES TO TARGET HIV PERSISTENCE

Current limitations of antiretroviral therapy are driving interest in novel HIV eradication strategies. Extracellular vesicles (EVs) are nano-sized membrane vesicles involved in cell signaling which have shown promise as engineerable therapeutic agents. We used surface display technology to engineer HIV-targeting EVs (HTEVs) that block HIV infection and target infected cells. EVs were isolated from healthy donor…

DEVELOPMENT OF A PSEUDOVIRUS DELIVERY SYSTEM FOR HIV-1 ELIMINATION

A key challenge in developing successful HIV-1 cure strategies rest in eliminating the integrated provirus from the genomes of infected CD4+ T lymphocytes and monocyte-macrophages. In a first step towards this end, we recently demonstrated success by the sequential use of long acting slow effective release (LASER) ART and CRISPR-Cas9 in achieving viral sterilization from…

EDITING OF SIV IN NONHUMAN PRIMATES BY CRISPR-CAS9 IN VIRAL RESERVOIRS

Antiretroviral therapy (ART) suppresses but does not eliminate replication competent HIV proviral DNA from latently infected cells, thus resulting in viral reactivation upon ART cessation. Therefore, removal of HIV proviral DNA from infected individuals is needed. We have assessed a CRISPR-Cas9 based gene editing strategy for the elimination of the SIV proviral DNA in the…

EFFICIENT DELETION OF CCR5 PROVIDES COMPLETE PROTECTION AGAINST HIV IN XENOGRAFT MICE

Hematopoietic stem cell transplant (HSCT) with CCR5d32/d32 defective stem cells has resulted in long-term remission of HIV infection in three patients (“Berlin”, “Dusseldorf”, and “Oxford”) that received allogeneic HSCT for co-occurring malignancies. However, the scarcity of HLA-matched, CCR5d32 homozygous stem cell donors represents a significant hurdle to more widespread adoption of HSCT for treatment of…

ANTAGONISM OF PPARG FOR TH17 MUCOSAL IMMUNITY RESTORATION AND HIV-RESERVOIR PURGING

The Th17-polarized CCR6+RORγt+CD4+T-cells are key players in mucosal homeostasis. These cells are preferential targets for HIV/SIV infection at mucosal sites and their depletion/functional alteration persist despite viral-suppressive antiretroviral therapy (ART) in people living with HIV (PLWH). Moreover, Th17 cells carrying replication-competent HIV persist during long-term ART. Therefore, novel Th17-targeted HIV remission/cure strategies are needed. Considering…